Pakistan · Delayed Price · Currency is PKR Citi Pharma Statistics
Total Valuation
Citi Pharma has a market cap or net worth of PKR 18.72 billion. The enterprise value is 20.61 billion.
| Market Cap | 18.72B |
| Enterprise Value | 20.61B |
Important Dates
The last earnings date was Wednesday, October 29, 2025.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | Oct 17, 2025 |
Share Statistics
Citi Pharma has 228.46 million shares outstanding. The number of shares has increased by 0.14% in one year.
| Current Share Class | 228.46M |
| Shares Outstanding | 228.46M |
| Shares Change (YoY) | +0.14% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 38.66% |
| Owned by Institutions (%) | 10.79% |
| Float | 135.64M |
Valuation Ratios
The trailing PE ratio is 20.95 and the forward PE ratio is 13.00.
| PE Ratio | 20.95 |
| Forward PE | 13.00 |
| PS Ratio | 1.41 |
| PB Ratio | 1.69 |
| P/TBV Ratio | 1.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.10, with an EV/FCF ratio of -23.05.
| EV / Earnings | 23.05 |
| EV / Sales | 1.55 |
| EV / EBITDA | 11.10 |
| EV / EBIT | 12.24 |
| EV / FCF | -23.05 |
Financial Position
The company has a current ratio of 1.36, with a Debt / Equity ratio of 0.25.
| Current Ratio | 1.36 |
| Quick Ratio | 0.66 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | 1.51 |
| Debt / FCF | -3.14 |
| Interest Coverage | 4.50 |
Financial Efficiency
Return on equity (ROE) is 10.58% and return on invested capital (ROIC) is 9.94%.
| Return on Equity (ROE) | 10.58% |
| Return on Assets (ROA) | 7.00% |
| Return on Invested Capital (ROIC) | 9.94% |
| Return on Capital Employed (ROCE) | 14.85% |
| Revenue Per Employee | 25.05M |
| Profits Per Employee | 1.68M |
| Employee Count | 531 |
| Asset Turnover | 0.88 |
| Inventory Turnover | 2.99 |
Taxes
In the past 12 months, Citi Pharma has paid 422.26 million in taxes.
| Income Tax | 422.26M |
| Effective Tax Rate | 32.07% |
Stock Price Statistics
The stock price has increased by +81.91% in the last 52 weeks. The beta is 0.49, so Citi Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | +81.91% |
| 50-Day Moving Average | 92.84 |
| 200-Day Moving Average | 89.86 |
| Relative Strength Index (RSI) | 35.17 |
| Average Volume (20 Days) | 1,693,985 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Citi Pharma had revenue of PKR 13.30 billion and earned 894.23 million in profits. Earnings per share was 3.91.
| Revenue | 13.30B |
| Gross Profit | 2.11B |
| Operating Income | 1.68B |
| Pretax Income | 1.32B |
| Net Income | 894.23M |
| EBITDA | 1.85B |
| EBIT | 1.68B |
| Earnings Per Share (EPS) | 3.91 |
Balance Sheet
The company has 915.49 million in cash and 2.81 billion in debt, giving a net cash position of -1.89 billion or -8.28 per share.
| Cash & Cash Equivalents | 915.49M |
| Total Debt | 2.81B |
| Net Cash | -1.89B |
| Net Cash Per Share | -8.28 |
| Equity (Book Value) | 11.07B |
| Book Value Per Share | 48.46 |
| Working Capital | 2.37B |
Cash Flow
In the last 12 months, operating cash flow was -730.01 million and capital expenditures -163.88 million, giving a free cash flow of -893.89 million.
| Operating Cash Flow | -730.01M |
| Capital Expenditures | -163.88M |
| Free Cash Flow | -893.89M |
| FCF Per Share | -3.91 |
Margins
Gross margin is 15.85%, with operating and profit margins of 12.66% and 6.72%.
| Gross Margin | 15.85% |
| Operating Margin | 12.66% |
| Pretax Margin | 9.90% |
| Profit Margin | 6.72% |
| EBITDA Margin | 13.92% |
| EBIT Margin | 12.66% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 3.50, which amounts to a dividend yield of 4.20%.
| Dividend Per Share | 3.50 |
| Dividend Yield | 4.20% |
| Dividend Growth (YoY) | 7.69% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 82.73% |
| Buyback Yield | -0.14% |
| Shareholder Yield | 4.06% |
| Earnings Yield | 4.78% |
| FCF Yield | -4.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 18, 2021. It was a forward split with a ratio of 1.1.
| Last Split Date | Oct 18, 2021 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
Citi Pharma has an Altman Z-Score of 2.95 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.95 |
| Piotroski F-Score | 4 |